# Stephan Stilgenbauer

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 602 papers | 30,596 citations | 85 h-index | 167 g-index |
| 639 ext. papers | 35,081 ext. citations | 5.1 avg, IF | 6.57 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 602 | KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.. *Lancet Haematology,the*, **2022**, 9, e133-e142 | 14.6 | 1 |
| 601 | Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.. *HemaSphere*, **2022**, 6, e692 | 0.3 | 1 |
| 600 | Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. *HemaSphere*, **2022**, 6, e729 | 0.3 | |
| 599 | Interleukin-10 receptor signaling promotes the maintenance of a PD-1 TCF-1 CD8 T´cell population that sustains anti-tumor immunity. *Immunity*, **2021**, | 32.3 | 8 |
| 598 | Activation of Notch and Myc signaling via B cell-restricted depletion of Dnmt3a generates a consistent murine model of chronic lymphocytic leukemia. *Cancer Research*, **2021**, | 10.1 | 1 |
| 597 | IgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in south-west Germany: A seroprevalence study. *HIV Medicine*, **2021**, | 2.7 | 1 |
| 596 | Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older. *Blood*, **2021**, 138, 1552-1552 | 2.2 | 1 |
| 595 | Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial. *Blood*, **2021**, 138, 2639-2639 | 2.2 | |
| 594 | Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). *Blood*, **2021**, 138, 3721-3721 | 2.2 | |
| 593 | The CLL12 trial: Ibrutinib versus placebo in treatment-naïve, early stage chronic lymphocytic leukemia. *Blood*, **2021**, | 2.2 | 5 |
| 592 | Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy. *American Journal of Hematology*, **2021**, | 7.1 | 1 |
| 591 | High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial. *Blood*, **2021**, 138, 72-72 | 2.2 | |
| 590 | A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. *Blood*, **2021**, 138, 71-71 | 2.2 | 5 |
| 589 | Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). *Haematologica*, **2021**, 106, 2834-2844 | 6.6 | 1 |
| 588 | Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial. *Leukemia and Lymphoma*, **2021**, 1-9 | 1.9 | |
| 587 | Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. *Journal of Clinical Oncology*, **2021**, JCO2101181 | 2.3 | 10 |
| 586 | Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma. *Haematologica*, **2021**, 106, 2224-2232 | 6.6 | 6 |

| | | | |
|---|---|---|---|
| 585 | Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. *Haematologica*, **2021**, | 6.6 | 1 |
| 584 | EOMES is essential for antitumor activity of CD8 T cells in chronic lymphocytic leukemia. *Leukemia*, **2021**, 35, 3152-3162 | 10.7 | 4 |
| 583 | MARCKS affects cell motility and response to BTK inhibitors in CLL. *Blood*, **2021**, 138, 544-556 | 2.2 | 2 |
| 582 | Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune)therapy. *Haematologica*, **2021**, | 6.6 | 3 |
| 581 | Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients. *European Journal of Immunology*, **2021**, 51, 1449-1460 | 6.1 | 3 |
| 580 | B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. *Blood*, **2021**, 137, 2267-2271 | 2.2 | 3 |
| 579 | FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 3550-3559 | 8.8 | 4 |
| 578 | Discovery of Candidate DNA Methylation Cancer Driver Genes. *Cancer Discovery*, **2021**, 11, 2266-2281 | 24.4 | 12 |
| 577 | Current Treatment Options in CLL. *Cancers*, **2021**, 13, | 6.6 | 4 |
| 576 | Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas. *Leukemia*, **2021**, 35, 2002-2016 | 10.7 | 3 |
| 575 | Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization. *American Journal of Hematology*, **2021**, 96, E311-E314 | 7.1 | 2 |
| 574 | Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. *Blood*, **2021**, 138, 1805-1816 | 2.2 | 1 |
| 573 | Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. *Leukemia*, **2021**, 35, 3059-3072 | 10.7 | 6 |
| 572 | Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. *Journal of Clinical Oncology*, **2021**, 39, 3441-3452 | 2.2 | 65 |
| 571 | Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study. *Haematologica*, **2021**, 106, 682-691 | 6.6 | 3 |
| 570 | Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. *Haematologica*, **2021**, 106, 968-977 | 6.6 | 16 |
| 569 | Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. *Haematologica*, **2021**, 106, 859-862 | 6.6 | 4 |
| 568 | Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial. *Haematologica*, **2021**, 106, 543-554 | 6.6 | 6 |

| | | | |
|---|---|---|---|
| 567 | Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy. *Bone Marrow Transplantation*, **2021**, 56, 195-201 | 4.4 | 2 |
| 566 | Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. *Blood*, **2021**, 137, 1365-1376 | 2.2 | 26 |
| 565 | U-RT1 - A new model for Richter transformation. *Neoplasia*, **2021**, 23, 140-148 | 6.4 | 2 |
| 564 | No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. *Leukemia and Lymphoma*, **2021**, 62, 837-845 | 1.9 | |
| 563 | Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study. *Bone Marrow Transplantation*, **2021**, 56, 692-695 | 4.4 | 1 |
| 562 | LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. *Blood*, **2021** , 137, 3251-3258 | 2.2 | 1 |
| 561 | EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4 T cells in chronic lymphocytic leukemia. *Leukemia*, **2021**, 35, 2311-2324 | 10.7 | 7 |
| 560 | Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. *British Journal of Haematology*, **2021**, 193, 325-338 | 4.5 | 3 |
| 559 | Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients. *Leukemia*, **2021**, | 10.7 | 1 |
| 558 | Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. *Leukemia and Lymphoma*, **2021**, 1-12 | 1.9 | 1 |
| 557 | Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019. *Intensive Care Medicine Experimental*, **2021**, 9, 45 | 3.7 | 2 |
| 556 | Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. *Lancet Haematology,the*, **2021**, 8, e648-e657 | 14.6 | 6 |
| 555 | Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. *Nature Communications*, **2021**, 12, 5395 | 17.4 | 1 |
| 554 | Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia.. *Blood*, **2021**, | 2.2 | 6 |
| 553 | Role of Specific B-Cell Receptor Antigens in Lymphomagenesis. *Frontiers in Oncology*, **2020**, 10, 604685 | 5.3 | 4 |
| 552 | DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy. *Scientific Data*, **2020**, 7, 133 | 8.2 | 1 |
| 551 | Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1575-1580 | 4.7 | 12 |
| 550 | Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. *Blood*, **2020**, 135, 2402-2412 | 2.2 | 43 |

| | | | |
|---|---|---|---|
| 549 | International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. *Blood*, **2020**, 135, 1859-1869 | 2.2 | 45 |
| 548 | Noncatalytic Bruton's tyrosine kinase activates PLC variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells. *Journal of Biological Chemistry*, **2020**, 295, 5717-5736 | 5.4 | 16 |
| 547 | Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL. *Genome Medicine*, **2020**, 12, 29 | 14.4 | 8 |
| 546 | Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. *Expert Opinion on Pharmacotherapy*, **2020**, 21, 917-929 | 4 | 13 |
| 545 | Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. *Clinical Cancer Research*, **2020**, 26, 2096-2103 | 12.9 | 18 |
| 544 | COVID-19 among fit patients with CLL treated with venetoclax-based combinations. *Leukemia*, **2020**, 34, 2225-2229 | 10.7 | 25 |
| 543 | Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm. *Current Oncology Reports*, **2020**, 22, 16 | 6.3 | 14 |
| 542 | Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). *Haematologica*, **2020**, 105, 2598-2607 | 6.6 | 20 |
| 541 | Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. *Leukemia*, **2020**, 34, 2038-2050 | 10.7 | 19 |
| 540 | is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 4320-4327 | 11.5 | 24 |
| 539 | Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group. *Leukemia*, **2020**, 34, 1038-1051 | 10.7 | 14 |
| 538 | Stromal cell protein kinase C- inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance. *Science Translational Medicine*, **2020**, 12, | 17.5 | 10 |
| 537 | Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. *Haematologica*, **2020**, 105, 2440-2447 | 6.6 | 14 |
| 536 | Robust Discovery of Candidate DNA Methylation Cancer Drivers. *Blood*, **2020**, 136, 33-34 | 2.2 | |
| 535 | Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.. *Journal of Clinical Oncology*, **2020**, 38, 8027-8027 | 2.2 | 2 |
| 534 | Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia. *Genes Chromosomes and Cancer*, **2020**, 59, 261-267 | 5 | 7 |
| 533 | Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. *Haematologica*, **2020**, 105, 1379-1390 | 6.6 | 7 |
| 532 | Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. *Leukemia*, **2020**, 34, 1177-1181 | 10.7 | 3 |

| | | | |
|---|---|---|---|
| 531 | TBET-expressing Th1 CD4 T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in Eμ-TCL1 mice. *British Journal of Haematology*, **2020**, 189, 133-145 | 4.5 | 7 |
| 530 | Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cells. *Leukemia*, **2020**, 34, 1125-1134 | 10.7 | 3 |
| 529 | Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma. *Frontiers in Oncology*, **2020**, 10, 580364 | 5.3 | 1 |
| 528 | Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab. *Frontiers in Oncology*, **2020**, 10, 1578 | 5.3 | 26 |
| 527 | Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncology, The*, **2020**, 21, 1188-1200 | 21.7 | 92 |
| 526 | Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. *Haematologica*, **2020**, 105, 170-181 | 6.6 | 19 |
| 525 | Cryptic insertion of exons 2 and 3 into the immunoglobulin heavy chain locus detected by whole genome sequencing in a case of "-negative" Burkitt lymphoma. *Haematologica*, **2020**, 105, e202-e205 | 6.6 | 15 |
| 524 | The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. *Leukemia*, **2020**, 34, 296-300 | 10.7 | 15 |
| 523 | Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. *Leukemia*, **2020**, 34, 115-127 | 10.7 | 9 |
| 522 | Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. *Leukemia*, **2020**, 34, 441-450 | 10.7 | 4 |
| 521 | Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential. *Cancer Immunology, Immunotherapy*, **2020**, 69, 1535-1548 | 7.4 | 2 |
| 520 | High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. *Blood*, **2020**, 135, 866-870 | 2.2 | 18 |
| 519 | Telomere Dysfunction in Chronic Lymphocytic Leukemia. *Frontiers in Oncology*, **2020**, 10, 612665 | 5.3 | 2 |
| 518 | Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis. *Frontiers in Oncology*, **2020**, 10, 637161 | 5.3 | 2 |
| 517 | Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. *Lancet Oncology, The*, **2019**, 20, 1576-1586 | 21.7 | 11 |
| 516 | Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia. *Cancers*, **2019**, 11, | 6.6 | 2 |
| 515 | Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). *American Journal of Hematology*, **2019**, 94, 1002-1006 | 7.1 | 3 |
| 514 | Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. *New England Journal of Medicine*, **2019**, 380, 2225-2236 | 59.2 | 368 |

| | | | |
|---|---|---|---|
| 513 | Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks. *Molecular Systems Biology*, **2019**, 15, e8339 | 12.2 | 20 |
| 512 | Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. *Leukemia*, **2019**, 33, 2531-2535 | 10.7 | 14 |
| 511 | Venetoclax resistance and acquired mutations in chronic lymphocytic leukemia. *Haematologica*, **2019**, 104, e434-e437 | 6.6 | 81 |
| 510 | IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia. *Blood*, **2019**, 134, 534-547 | 2.2 | 25 |
| 509 | MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma. *Cancer Research*, **2019**, 79, 3125-3138 | 10.1 | 8 |
| 508 | Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. *Journal of Clinical Oncology*, **2019**, 37, 1391-1402 | 2.2 | 109 |
| 507 | Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. *Blood*, **2019**, 134, 111-122 | 2.2 | 94 |
| 506 | Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. *Leukemia*, **2019**, 33, 2183-2194 | 10.7 | 14 |
| 505 | Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. *Nature Communications*, **2019**, 10, 1459 | 17.4 | 49 |
| 504 | Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement. *British Journal of Haematology*, **2019**, 186, e203-e207 | 4.5 | 5 |
| 503 | Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 715-722.e6 | 2 | 22 |
| 502 | Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. *Cell Death and Disease*, **2019**, 10, 571 | 9.8 | 18 |
| 501 | Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy. *Blood*, **2019**, 134, 3035-3035 | 2.2 | 1 |
| 500 | Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group. *Blood*, **2019**, 134, 3040-3040 | 2.2 | 1 |
| 499 | Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. *Blood*, **2019**, 134, 36-36 | 2.2 | 15 |
| 498 | Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial). *Blood*, **2019**, 134, 1754-1754 | 2.2 | 7 |
| 497 | Role of FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Aggressive Non-Hodgkin Lymphoma. *Blood*, **2019**, 134, 2892-2892 | 2.2 | 2 |
| 496 | Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up. *Blood*, **2019**, 134, 3308-3308 | 2.2 | 2 |

| | | | |
|---|---|---|---|
| 495 | A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). *Blood*, **2019**, 134, 4297-4297 | 2.2 | 5 |
| 494 | A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). *Blood*, **2019**, 134, 3047-3047 | 2.2 | 3 |
| 493 | Inherited DNA repair and cell cycle gene defects in chronic lymphocytic leukemia.. *Journal of Clinical Oncology*, **2019**, 37, 1508-1508 | 2.2 | 2 |
| 492 | Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial.. *Journal of Clinical Oncology*, **2019**, 37, 7523-7523 | 2.2 | 4 |
| 491 | CLL with Del (17p)/TP53 Mutation. *Hematologic Malignancies*, **2019**, 97-106 | 0 | |
| 490 | Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.. *Journal of Clinical Oncology*, **2019**, 37, 7502-7502 | 2.2 | |
| 489 | Eomes and IL-10 Regulate Anti-Tumor Activity of T Cells in Chronic Lymphocytic Leukemia. *Blood*, **2019**, 134, 4288-4288 | 2.2 | |
| 488 | Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors. *Blood*, **2019**, 134, 4275-4275 | 2.2 | |
| 487 | Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2. *Blood*, **2019**, 134, 1507-1507 | 2.2 | 1 |
| 486 | The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models. *Blood*, **2019**, 134, 2860-2860 | 2.2 | |
| 485 | Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies. *Blood*, **2019**, 134, 5616-5616 | 2.2 | |
| 484 | Telomere Shortening By Terc Knockout in the Eμ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival. *Blood*, **2019**, 134, 1732-1732 | 2.2 | |
| 483 | Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia. *Blood*, **2019**, 134, 3954-3954 | 2.2 | |
| 482 | Response to Comment by Jonathan Weiss. *Haematologica*, **2019**, 104, e542 | 6.6 | 1 |
| 481 | Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. *Lancet, The*, **2019**, 394, 2271-2281 | 40 | 85 |
| 480 | From Biology to Therapy: The CLL Success Story. *HemaSphere*, **2019**, 3, e175 | 0.3 | 29 |
| 479 | PI3K inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. *Leukemia*, **2019**, 33, 1427-1438 | 10.7 | 36 |
| 478 | CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. *Leukemia*, **2019**, 33, 1161-1172 | 10.7 | 26 |

| | | | |
|---|---|---|---|
| 477 | The involvement of microRNA in the pathogenesis of Richter syndrome. *Haematologica*, **2019**, 104, 100-110 | 6.6 | 15 |
| 476 | Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. *Blood*, **2019**, 133, 494-497 | 2.2 | 18 |
| 475 | mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. *Blood*, **2019**, 133, 830-839 | 2.2 | 33 |
| 474 | New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. *Leukemia and Lymphoma*, **2019**, 60, 649-657 | 1.9 | 10 |
| 473 | Control of chronic lymphocytic leukemia development by clonally-expanded CD8 T-cells that undergo functional exhaustion in secondary lymphoid tissues. *Leukemia*, **2019**, 33, 625-637 | 10.7 | 42 |
| 472 | Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial. *British Journal of Haematology*, **2019**, 184, 833-836 | 4.5 | 4 |
| 471 | Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. *British Journal of Haematology*, **2018**, 180, 666-679 | 4.5 | 38 |
| 470 | Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. *Haematologica*, **2018**, 103, 688-697 | 6.6 | 13 |
| 469 | iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*, **2018**, 131, 2745-2760 | 2.2 | 607 |
| 468 | CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. *Future Oncology*, **2018**, 14, 499-513 | 3.6 | 20 |
| 467 | Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. *Leukemia and Lymphoma*, **2018**, 59, 1614-1623 | 1.9 | 11 |
| 466 | NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. *International Journal of Cancer*, **2018**, 142, 322-333 | 7.5 | 24 |
| 465 | Venetoclax: Targeting BCL2 in Hematological Cancers. *Recent Results in Cancer Research*, **2018**, 212, 215-242 | 2.5 | 13 |
| 464 | Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. *Haematologica*, **2018**, 103, 1889-1898 | 6.6 | 13 |
| 463 | High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. *Blood*, **2018**, 132, 892-902 | 2.2 | 64 |
| 462 | Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. *Leukemia*, **2018**, 32, 1778-1786 | 10.7 | 20 |
| 461 | Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2018**, 19, 1215-1228 | 21.7 | 70 |
| 460 | Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. *British Journal of Haematology*, **2018**, 182, 504-512 | 4.5 | 32 |

| | | | |
|---|---|---|---|
| 459 | Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2018**, 24, 4371-4379 | 12.9 | 90 |
| 458 | Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia. *Blood*, **2018**, 132, 3134-3134 | 2.2 | 3 |
| 457 | Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA. *Blood*, **2018**, 132, 781-781 | 2.2 | 8 |
| 456 | Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). *Blood*, **2018**, 132, 694-694 | 2.2 | 6 |
| 455 | Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). *Blood*, **2018**, 132, 4430-4430 | 2.2 | 1 |
| 454 | Identification of Posttranvslationally Modified Neoantigens As Targets of B Cell Receptors of Burkitt Lymphoma. *Blood*, **2018**, 132, 1588-1588 | 2.2 | 2 |
| 453 | Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. *Blood*, **2018**, 132, 1856-1856 | 2.2 | 2 |
| 452 | Hypophosphatemia after High Dosage Iron Substitution with Ferric Carboxymaltose (FCM) and Iron Isomaltoside (IM) the Randomised Controlled Home Afers 1 Trial. *Blood*, **2018**, 132, 3627-3627 | 2.2 | 4 |
| 451 | Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy. *Blood*, **2018**, 132, 4433-4433 | 2.2 | 2 |
| 450 | NOTCH1 Signaling Is Activated in CLL By Mutations of FBXW7 and Low Expression of USP28 at 11q23. *Blood*, **2018**, 132, 946-946 | 2.2 | 1 |
| 449 | Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model. *Blood*, **2018**, 132, 1868-1868 | 2.2 | 1 |
| 448 | The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study. *Blood*, **2018**, 132, 3140-3140 | 2.2 | 1 |
| 447 | Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). *Blood*, **2018**, 132, 1859-1859 | 2.2 | 0 |
| 446 | Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study).. *Journal of Clinical Oncology*, **2018**, 36, 12048-12048 | 2.2 | 1 |
| 445 | The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.. *Journal of Clinical Oncology*, **2018**, 36, 7533-7533 | 2.2 | 1 |
| 444 | The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL).. *Journal of Clinical Oncology*, **2018**, 36, TPS7582-TPS7582 | 2.2 | 4 |
| 443 | A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. *Journal of Clinical Oncology*, **2018**, 36, TPS7588-TPS7588 | 2.2 | 2 |
| 442 | Functional characterization of phospholipase C- mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder. *Oncotarget*, **2018**, 9, 34357-34378 | 3.3 | 11 |

| | | | |
|---|---|---|---|
| 441 | B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide.. *Journal of Clinical Oncology*, **2018**, 36, 7531-7531 | 2.2 | |
| 440 | Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia.. *Journal of Clinical Oncology*, **2018**, 36, 7513-7513 | 2.2 | |
| 439 | Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).. *Journal of Clinical Oncology*, **2018**, 36, 7521-7521 | 2.2 | |
| 438 | Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL.. *Journal of Clinical Oncology*, **2018**, 36, 7526-7526 | 2.2 | 1 |
| 437 | Gene Set Enrichment Analysis Suggests That Increased Rituximab-Mediated NK Cell Cytotoxicity after Vitamin D Substitution Is Driven By Upregulation of Interferon Alpha (IFN-a) Isoforms. *Blood*, **2018**, 132, 3696-3696 | 2.2 | |
| 436 | Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL. *Blood*, **2018**, 132, 583-583 | 2.2 | |
| 435 | Modeling of the Epigenome of the Cell-of-Origin Identifies Cancer-Specific DNA Methylation Patterns in CLL. *Blood*, **2018**, 132, 3885-3885 | 2.2 | |
| 434 | Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). *Blood*, **2018**, 132, 4429-4429 | 2.2 | |
| 433 | MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy. *Blood*, **2018**, 132, 1866-1866 | 2.2 | |
| 432 | Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option. *Blood*, **2018**, 132, 1580-1580 | 2.2 | |
| 431 | BAR-Bodies: B-Cell Receptor Antigens As the Targeting Moiety of Antibodies in Substitution for the Variable Region of Heavy and Light Chains. *Blood*, **2018**, 132, 2940-2940 | 2.2 | 0 |
| 430 | Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. *Journal of Clinical Oncology*, **2018**, 36, 1973-1980 | 2.2 | 174 |
| 429 | aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. *Haematologica*, **2018**, 103, 1956-1968 | 6.6 | 43 |
| 428 | Outcome of patients aged 80´years or older treated for chronic lymphocytic leukaemia. *British Journal of Haematology*, **2018**, 183, 727-735 | 4.5 | 6 |
| 427 | The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. *Blood*, **2018**, 132, 2446-2455 | 2.2 | 184 |
| 426 | IG- neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. *Blood*, **2018**, 132, 2280-2285 | 2.2 | 19 |
| 425 | Chronische Lymphatische Leukämie. *Klinikarzt*, **2018**, 47, 412-417 | 0 | |
| 424 | Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. *Leukemia and Lymphoma*, **2017**, 58, 348-356 | 1.9 | 2 |

| | | | |
|---|---|---|---|
| 423 | Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2017**, 23, 4527-4533 | 12.9 | 43 |
| 422 | Front-line treatment of CLL in the era of novel agents. *Cancer Treatment Reviews*, **2017**, 53, 70-78 | 14.4 | 19 |
| 421 | Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Oncology, The*, **2017**, 18, 297-311 | 21.7 | 173 |
| 420 | Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 1054-1067.e10 | 11.5 | 72 |
| 419 | Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. *Clinical Cancer Research*, **2017**, 23, 5292-5301 | 12.9 | 20 |
| 418 | TP53 mutation and survival in aggressive B cell lymphoma. *International Journal of Cancer*, **2017**, 141, 1381-1388 | 7.5 | 39 |
| 417 | Ibrutinib-resistant CLL: unwanted and unwonted!. *Blood*, **2017**, 129, 1407-1409 | 2.2 | 5 |
| 416 | Venetoclax and obinutuzumab in chronic lymphocytic leukemia. *Blood*, **2017**, 129, 2702-2705 | 2.2 | 90 |
| 415 | Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial. *British Journal of Haematology*, **2017**, 179, 342-346 | 4.5 | 2 |
| 414 | Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. *Lancet Haematology,the*, **2017**, 4, e510-e523 | 14.6 | 157 |
| 413 | Analysis of rare germ line variants in chronic lymphocytic leukemia. *Blood*, **2017**, 130, 2443-2444 | 2.2 | 4 |
| 412 | Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. *OncoTargets and Therapy*, **2017**, 10, 645-656 | 4.4 | 7 |
| 411 | Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges. *Journal of Oncology Practice*, **2017**, 13, 381-382 | 3.1 | 1 |
| 410 | Tumor-derived exosomes modulate PD-L1 expression in monocytes. *Science Immunology*, **2017**, 2, | 28 | 170 |
| 409 | Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. *Lancet Haematology,the*, **2017**, 4, e475-e486 | 14.6 | 36 |
| 408 | Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. *Blood*, **2017**, 130, 1477-1480 | 2.2 | 49 |
| 407 | Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. *Nature Communications*, **2017**, 8, 153 | 17.4 | 29 |
| 406 | Rapid detection of ATM/p53 function with p27Kip FACS analysis: a novel diagnostic tool for chronic lympocytic leukemia?. *Leukemia and Lymphoma*, **2017**, 58, 6-7 | 1.9 | 1 |

| | | | |
|---|---|---|---|
| 405 | Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. *European Journal of Haematology*, **2017**, 98, 254-262 | 3.8 | 7 |
| 404 | COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)A two-cohort phase II study.. *Journal of Clinical Oncology*, **2017**, 35, TPS7567-TPS7567 | 2.2 | |
| 403 | Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. *Journal of Clinical Oncology*, **2016**, 34, 3758-3765 | 2.2 | 111 |
| 402 | Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. *Lancet Oncology, The*, **2016**, 17, 1409-1418 | 21.7 | 233 |
| 401 | The Phospholipase C Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein. *Journal of Biological Chemistry*, **2016**, 291, 22136-22148 | 5.4 | 29 |
| 400 | Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model. *Acta Neuropathologica Communications*, **2016**, 4, 87 | 7.3 | 28 |
| 399 | Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. *Lancet, The*, **2016**, 388, 565-75 | 40 | 233 |
| 398 | Krüppel-like factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling. *Haematologica*, **2016**, 101, e249-53 | 6.6 | 17 |
| 397 | Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. *OncoImmunology*, **2016**, 5, e1150399 | 7.2 | 55 |
| 396 | DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. *Nature Genetics*, **2016**, 48, 253-64 | 36.3 | 193 |
| 395 | Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia. *Oncology Research and Treatment*, **2016**, 39, 34-40 | 2.8 | 3 |
| 394 | Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. *Leukemia and Lymphoma*, **2016**, 57, 789-96 | 1.9 | 66 |
| 393 | In Vivo modeling of Resistance to PI3K Inhibitor Treatment Using EμTCL1-Tg Tumor Transfer Model. *Blood*, **2016**, 128, 190-190 | 2.2 | 4 |
| 392 | Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 192-192 | 2.2 | 10 |
| 391 | 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. *Blood*, **2016**, 128, 2042-2042 | 2.2 | 6 |
| 390 | Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety | 2.2 | 4 |
| 389 | Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). *Blood*, **2016**, 128, 2054-2054 | 2.2 | 8 |
| 388 | Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). *Blood*, **2016**, 128, 229-229 | 2.2 | 10 |

| | | | |
|---|---|---|---|
| 387 | Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL. *Blood*, **2016**, 128, 231-231 | 2.2 | 4 |
| 386 | Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment. *Blood*, **2016**, 128, 2770-2770 | 2.2 | 16 |
| 385 | CLL Exosome-Derived Y RNA hY4 Induces TLR7/8-Mediated Inflammation and PD-L1 Expression in Monocytes. *Blood*, **2016**, 128, 3217-3217 | 2.2 | 1 |
| 384 | Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group. *Blood*, **2016**, 128, 3227-3227 | 2.2 | 13 |
| 383 | Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 3230-3230 | 2.2 | 11 |
| 382 | Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. *Blood*, **2016**, 128, 4376-4376 | 2.2 | 1 |
| 381 | Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). *Blood*, **2016**, 128, 4382-4382 | 2.2 | 9 |
| 380 | Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 4393-4393 | 2.2 | 16 |
| 379 | Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 4395-4395 | 2.2 | 6 |
| 378 | Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11 Study Population. *Blood*, **2016**, 128, 4401-4401 | 2.2 | 8 |
| 377 | Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. *Blood*, **2016**, 128, 511-511 | 2.2 | 13 |
| 376 | CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial. *Blood*, **2016**, 128, 640-640 | 2.2 | 9 |
| 375 | Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial. *Blood*, **2016**, 128, 682-682 | 2.2 | 3 |
| 374 | In Chronic Lymphocytic Leukemia □T7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation. *Blood*, **2016**, 128, 971-971 | 2.2 | |
| 373 | High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group. *Blood*, **2016**, 128, 781-781 | 2.2 | |
| 372 | Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG). *Blood*, **2016**, 128, 4394-4394 | 2.2 | 0 |
| 371 | Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response. *Blood*, **2016**, 128, 1081-1081 | 2.2 | 0 |
| 370 | Assessment of Measures to Reduce Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab in the GREEN Study. *Blood*, **2016**, 128, 5589-5589 | 2.2 | |

| | | | |
|---|---|---|---|
| 369 | Telomere dysfunction and chromothripsis. *International Journal of Cancer*, **2016**, 138, 2905-14 | 7.5 | 34 |
| 368 | Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. *European Journal of Haematology*, **2016**, 97, 253-60 | 3.8 | 18 |
| 367 | Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis. *Haematologica*, **2016**, 101, 1380-1389 | 6.6 | 31 |
| 366 | Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. *Lancet Oncology, The*, **2016**, 17, 768-778 | 21.7 | 536 |
| 365 | First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. *Lancet Oncology, The*, **2016**, 17, 928-942 | 21.7 | 416 |
| 364 | Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. *Journal of Clinical Oncology*, **2016**, 34, 1386-94 | 2.2 | 197 |
| 363 | Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. *Lancet Haematology,the*, **2016**, 3, e217-27 | 14.6 | 288 |
| 362 | Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. *Leukemia and Lymphoma*, **2016**, 57, 1291-9 | 1.9 | 16 |
| 361 | Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. *Blood*, **2016**, 127, 208-15 | 2.2 | 442 |
| 360 | Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. *Blood*, **2016**, 128, 395-404 | 2.2 | 92 |
| 359 | Postibrutinib outcomes in patients with mantle cell lymphoma. *Blood*, **2016**, 127, 1559-63 | 2.2 | 171 |
| 358 | High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. *Lancet Haematology,the*, **2016**, 3, e388-97 | 14.6 | 93 |
| 357 | Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 2117-2125 | 4.7 | 70 |
| 356 | Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. *Haematologica*, **2015**, 100, 511-6 | 6.6 | 34 |
| 355 | Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. *Leukemia Research*, **2015**, 39, 495-500 | 2.7 | 41 |
| 354 | Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. *Haematologica*, **2015**, 100, e311-4 | 6.6 | 12 |
| 353 | Mutations driving CLL and their evolution in progression and relapse. *Nature*, **2015**, 526, 525-30 | 50.4 | 658 |
| 352 | Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody. *Oncology Research and Treatment*, **2015**, 38, 185-92 | 2.8 | 36 |

| | | | |
|---|---|---|---|
| 351 | The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. *Future Oncology*, **2015**, 11, 1895-903 | 3.6 | 27 |
| 350 | MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E5261-70 | 11.5 | 75 |
| 349 | Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). *Haematologica*, **2015**, 100, 1451-9 | 6.6 | 26 |
| 348 | Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6. *International Journal of Cancer*, **2015**, 136, 65-73 | 7.5 | 11 |
| 347 | Prognostic markers and standard management of chronic lymphocytic leukemia. *Hematology American Society of Hematology Education Program*, **2015**, 2015, 368-77 | 3.1 | 24 |
| 346 | Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia. *International Journal of Cancer*, **2015**, 137, 2959-70 | 7.5 | 14 |
| 345 | Management of chronic lymphocytic leukemia. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2015**, 164-75 | 7.1 | 20 |
| 344 | Epigenetic silencing of miR-708 enhances NF-B signaling in chronic lymphocytic leukemia. *International Journal of Cancer*, **2015**, 137, 1352-61 | 7.5 | 40 |
| 343 | How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?. *Leukemia and Lymphoma*, **2015**, 56, 587-93 | 1.9 | 13 |
| 342 | Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 2436-2436 | 2.2 | 1 |
| 341 | Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. *Blood*, **2015**, 126, 2934-2934 | 2.2 | 5 |
| 340 | Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy. *Blood*, **2015**, 126, 362-362 | 2.2 | 3 |
| 339 | CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial. *Blood*, **2015**, 126, 4151-4151 | 2.2 | 7 |
| 338 | Prognostic Impact and Risk Factors of Reducing Prescribed Doses of Fludarabine, Cyclophosphamide and Rituximab (FCR) during Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). *Blood*, **2015**, 126, 4156-4156 | 2.2 | 12 |
| 337 | Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study. *Blood*, **2015**, 126, 493-493 | 2.2 | 11 |
| 336 | Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. *Blood*, **2015**, 126, 496-496 | 2.2 | 14 |
| 335 | Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity. *Blood*, **2015**, 126, 821-821 | 2.2 | 1 |
| 334 | Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 829-829 | 2.2 | 5 |

| | | | |
|---|---|---|---|
| 333 | Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study. *Blood*, **2015**, 126, 833-833 | 2.2 | 4 |
| 332 | Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 903-903 | 2.2 | 1 |
| 331 | Eμ-TCL1mTerc -/- Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 1724-1724 | 2.2 | |
| 330 | Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 365-365 | 2.2 | |
| 329 | Microenvironmental Stromal Cells Rescue CLL Cells from Apoptosis Via Hypoxia That Can be Targeted Therapeutically. *Blood*, **2015**, 126, 4140-4140 | 2.2 | |
| 328 | CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. *Blood*, **2015**, 126, 5263-5263 | 2.2 | |
| 327 | Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL. *Blood*, **2015**, 126, 1747-1747 | 2.2 | |
| 326 | Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *New England Journal of Medicine*, **2014**, 370, 997-1007 | 59.2 | 1303 |
| 325 | Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *New England Journal of Medicine*, **2014**, 370, 1101-10 | 59.2 | 1048 |
| 324 | Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. *Blood*, **2014**, 124, 49-62 | 2.2 | 202 |
| 323 | Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *New England Journal of Medicine*, **2014**, 370, 2286-94 | 59.2 | 800 |
| 322 | Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. *Journal of Clinical Oncology*, **2014**, 32, 1338-46 | 2.2 | 112 |
| 321 | Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. *Cancer Discovery*, **2014**, 4, 348-61 | 24.4 | 115 |
| 320 | Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. *Haematologica*, **2014**, 99, 1095-100 | 6.6 | 74 |
| 319 | MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. *Haematologica*, **2014**, 99, 1285-91 | 6.6 | 1 |
| 318 | Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. *Blood*, **2014**, 123, 3247-54 | 2.2 | 352 |
| 317 | PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. *Blood*, **2014**, 124, 420-5 | 2.2 | 11 |
| 316 | Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. *Blood*, **2014**, 124, 3841-9 | 2.2 | 158 |

| | | | |
|---|---|---|---|
| 315 | Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. *American Journal of Hematology*, **2014**, 89, E239-43 | 7.1 | 55 |
| 314 | Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. *British Journal of Haematology*, **2014**, 167, 565-9 | 4.5 | 7 |
| 313 | Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). *Blood*, **2014**, 124, 19-19 | 2.2 | 40 |
| 312 | Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno)Therapy: Results from the CLL8 Trial. *Blood*, **2014**, 124, 1938-1938 | 2.2 | 3 |
| 311 | Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in Ultra High-risk CLL: Final Results from the CLL2O Phase II Study. *Blood*, **2014**, 124, 1991-1991 | 2.2 | 10 |
| 310 | Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911). *Blood*, **2014**, 124, 1992-1992 | 2.2 | 2 |
| 309 | Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG). *Blood*, **2014**, 124, 23-23 | 2.2 | 2 |
| 308 | Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma. *Blood*, **2014**, 124, 3067-3067 | 2.2 | 13 |
| 307 | Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE 17 Trial. *Blood*, **2014**, 124, 327-327 | 2.2 | 29 |
| 306 | Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG ) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. *Blood*, **2014**, 124, 330-330 | 2.2 | 54 |
| 305 | Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study. *Blood*, **2014**, 124, 3327-3327 | 2.2 | 5 |
| 304 | Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. *Blood*, **2014**, 124, 3337-3337 | 2.2 | 4 |
| 303 | Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). *Blood*, **2014**, 124, 3345-3345 | 2.2 | 8 |
| 302 | Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. *Blood*, **2014**, 124, 4453-4453 | 2.2 | 11 |
| 301 | Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). *Blood*, **2014**, 124, 4699-4699 | 2.2 | 2 |
| 300 | Advances in treating chronic lymphocytic leukemia. *F1000prime Reports*, **2014**, 6, 65 | | 12 |
| 299 | Identification of the Antigenic Targets of the Major CLL-Derived Stereotyped BCRs and First Demonstration of Sub-Subsets. *Blood*, **2014**, 124, 298-298 | 2.2 | |
| 298 | Charting Unique Signatures of Somatic Hypermutation Amongst Chronic Lymphocytic Leukemia Patients Expressing IGHV4-34 Clonotypic B Cell Receptors. *Blood*, **2014**, 124, 1969-1969 | 2.2 | |

| | | | |
|---|---|---|---|
| 297 | Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial. *Blood*, **2014**, 124, 1951-1951 | 2.2 | |
| 296 | Chronic Lymphocytic Leukemia-Derived Extracellular Vesicles Contain a Distinctive Proteome, As Well As Specific Micro RNAs and Y RNAs. *Blood*, **2014**, 124, 1968-1968 | 2.2 | 1 |
| 295 | NFATc1 Is Transcriptionally Activated in Chronic Lymphocytic Leukemia (CLL) By Promotor DNA-Hypomethylation Which Correlates with in-Vitro Vulnerability to Calcineurin Inhibitors. *Blood*, **2014**, 124, 1941-1941 | 2.2 | |
| 294 | High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response?. *Blood*, **2014**, 124, 1964-1964 | 2.2 | |
| 293 | High Dose-Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation for Patients with Refractory or Recurrent Primary Central Nervous System Lymphoma Results of a Multicenter Study By the Germany Collaborative PCNSL Study Group. *Blood*, **2014**, 124, 2527-2527 | 2.2 | |
| 292 | Allogeneic HCT in Patients with 17p-CLL: Results of a Non-Interventional Study of the EBMT & Eric. *Blood*, **2014**, 124, 1224-1224 | 2.2 | |
| 291 | The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in Eμ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling. *Blood*, **2014**, 124, 1966-1966 | 2.2 | |
| 290 | High Resolution Genomic Profiling of Primary Ultra High Risk and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. *Blood*, **2014**, 124, 3288-3288 | 2.2 | |
| 289 | Genomic Mechanisms of 17p / TP53 Loss in Primary Ultra High-risk and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. *Blood*, **2014**, 124, 2184-2184 | 2.2 | |
| 288 | Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed By Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-Trial (T-PLL2) Conducted By the German CLL Study Group (GCLLSG). *Blood*, 2014, 124, 1999-1999 | 2.2 | |
| 287 | MicroRNAs in Hematologic Malignancies **2014**, 67-95 | | |
| 286 | 17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach. *Hematology/Oncology Clinics of North America*, **2013**, 27, 289-301 | 3.1 | 10 |
| 285 | Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *New England Journal of Medicine*, **2013**, 369, 507-16 | 59.2 | 1139 |
| 284 | NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. *Blood*, **2013**, 122, 1266-70 | 2.2 | 57 |
| 283 | ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). *Annals of Oncology*, **2013**, 24, 561-76 | 10.3 | 162 |
| 282 | Missing the notch in NOTCH1. *Leukemia and Lymphoma*, **2013**, 54, 1579-80 | 1.9 | |
| 281 | Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórek płaszcza wyniki międzynarodowego, wielooośrodkowego, badania II fazy z ibrutynibem (PCI-32765) EHA Encore. *Acta Haematologica Polonica*, **2013**, 44, 314-318 | 0.4 | 1 |
| 280 | The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p. *British Journal of Haematology*, **2013**, 160, 53-62 | 4.5 | 7 |

| | | | |
|---|---|---|---|
| 279 | Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. *Blood*, **2013**, 121, 2503-11 | 2.2 | 37 |
| 278 | The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. *International Journal of Cancer*, **2013**, 133, 1489-96 | 7.5 | 37 |
| 277 | Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB. *PLoS Genetics*, **2013**, 9, e1003373 | 6 | 108 |
| 276 | Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2013**, 54, 1849-53 | 1.9 | 14 |
| 275 | Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. *Cancer*, **2013** , 119, 2258-67 | 6.4 | 44 |
| 274 | Extracellular vesicles in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2013**, 54, 1826-30 | 1.9 | 12 |
| 273 | Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. *Leukemia and Lymphoma*, **2013**, 54, 1821-2 | 1.9 | 22 |
| 272 | Chronische lymphatische Leukämie - Standardtherapien und vielversprechende neue Behandlungsansätze. *Klinikarzt*, **2013**, 42, 350-354 | 0 | |
| 271 | TCL1A and ATM are co-expressed in chronic lymphocytic leukemia cells without deletion of 11q. *Haematologica*, **2013**, 98, 269-73 | 6.6 | 4 |
| 270 | BRAF mutations in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2013**, 54, 1177-82 | 1.9 | 36 |
| 269 | Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells. *Blood*, **2013**, 121, 4708-17 | 2.2 | 33 |
| 268 | Telomere length in mantle cell lymphoma. *Blood*, **2013**, 121, 1184-7 | 2.2 | 15 |
| 267 | TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. *Blood*, **2013**, 121, 3284-8 | 2.2 | 79 |
| 266 | Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia. *PLoS ONE*, **2013**, 8, e55261 | 3.7 | 18 |
| 265 | Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia. *PLoS ONE*, **2013**, 8, e72107 | 3.7 | 22 |
| 264 | TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study). *Blood*, **2013**, 122, 1638-1638 | 2.2 | 3 |
| 263 | A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study. *Blood*, **2013**, 122, 1645-1645 | 2.2 | 2 |
| 262 | Role Of High-Dose Cytarabine and Total Body Irradiation Conditioning before Autologous Stem Cell Transplantation In Mantle Cell Lymphoma - A Comparison Of Nordic MCL2, HOVON 45, and European MCL Younger Trials. *Blood*, **2013**, 122, 3367-3367 | 2.2 | 4 |

| | | | |
|---|---|---|---|
| 261 | Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG). *Blood*, **2013**, 122, 4127-4127 | 2.2 | 4 |
| 260 | Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial. *Blood*, **2013**, | 2.2 | 26 |
| 259 | Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG). *Blood*, **2013**, 122, 526-526 | 2.2 | 33 |
| 258 | NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911). *Blood*, **2013**, 122, 527-527 | 2.2 | 7 |
| 257 | Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial. *Blood*, **2013**, 122, 6-6 | 2.2 | 12 |
| 256 | Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial. *Blood*, **2013**, 122, 671-671 | 2.2 | 3 |
| 255 | Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.. *Journal of Clinical Oncology*, **2013**, 31, 7004-7004 | 2.2 | 18 |
| 254 | Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).. *Journal of Clinical Oncology*, **2013**, 31, 7014-7014 | 2.2 | 16 |
| 253 | A comprehensive prognostic index for patients with CLL.. *Journal of Clinical Oncology*, **2013**, 31, 7015-7015 | 2.2 | 1 |
| 252 | Novel Gene Mutations In Chronic Lymphocytic Leukemia: Prevalence and Clinical Implications In A Series Of 3185 Cases - Initial Results From The European Research Initiative On CLL. *Blood*, **2013**, 122, 1614-1614 | 2.2 | |
| 251 | Microenvironmental Factors and The Role Of Tumor Necrosis Factor Receptor Type 1 (TNFR-1) In Chronic Lymphocytic Leukemia. *Blood*, **2013**, 122, 4149-4149 | 2.2 | |
| 250 | Heterogeneity and Evolution Of DNA Methylation In Chronic Lymphocytic Leukemia. *Blood*, **2013**, 122, 1626-1626 | 2.2 | |
| 249 | ADARB1 Is Involved In a Reduced Maturation Of The miR15a/Mir-16-1 Family In Chronic Lymphocytic Leukemia. *Blood*, **2013**, 122, 1252-1252 | 2.2 | |
| 248 | Prognostic Assessment In Patients With Chronic Lymphocytic Leukemia (CLL) In Clinical Practice: A European Research Initiative On CLL (ERIC) Survey. *Blood*, **2013**, 122, 4156-4156 | 2.2 | 1 |
| 247 | Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. *Blood*, **2012**, 119, 4851-9 | 2.2 | 26 |
| 246 | CLL and deletion 13q14: merely the miRs?. *Blood*, **2012**, 119, 2974-5 | 2.2 | 6 |
| 245 | Risk categories and refractory CLL in the era of chemoimmunotherapy. *Blood*, **2012**, 119, 4101-7 | 2.2 | 95 |
| 244 | Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. *Cancer Cell*, **2012**, 22, 167-79 | 24.3 | 212 |

| | | | |
|---|---|---|---|
| 243 | Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2012**, 53, 417-23 | 1.9 | 51 |
| 242 | Cellular origin and pathophysiology of chronic lymphocytic leukemia. *Journal of Experimental Medicine*, **2012**, 209, 2183-98 | 16.6 | 178 |
| 241 | High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. *Blood*, **2012**, 120, 4783-94 | 2.2 | 156 |
| 240 | Genetics in chronic lymphocytic leukemia **2012**, 16-24 | | |
| 239 | Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. *Journal of Clinical Oncology*, **2012**, 30, 980-8 | 2.2 | 334 |
| 238 | miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. *Cancer Research*, **2012**, 72, 1763-72 | 10.1 | 161 |
| 237 | Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. *Journal of Clinical Oncology*, **2012**, 30, 3209-16 | 2.2 | 332 |
| 236 | Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. *Journal of Clinical Oncology* , **2012**, 30, 2483-91 | 2.2 | 100 |
| 235 | Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. *Journal of Clinical Oncology*, **2012**, 30, 2211-7 | 2.2 | 83 |
| 234 | Assessment of p53 Functionality in Chronic Lymphocytic Leukemia by Different Assays; An Eric-Wide Approach.. *Blood*, **2012**, 120, 2872-2872 | 2.2 | 1 |
| 233 | Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg. *Blood*, **2012**, 120, 302-302 | 2.2 | 14 |
| 232 | Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study). *Blood*, **2012**, 120, 3925-3925 | 2.2 | 2 |
| 231 | Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial. *Blood*, **2012**, 120, 433-433 | 2.2 | 6 |
| 230 | Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, | 2.2 | 14 |
| 229 | Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW. *Blood*, **2012**, 120, 716-716 | 2.2 | 1 |
| 228 | SF3B1, NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial. *Blood*, **2012**, 120, 966-966 | 2.2 | 1 |
| 227 | Lenalidomide Reduces Survival of Chronic Lymphocytic Leukemia Cells in Primary Co-Cultures by Altering the Myeloid Microenvironment. *Blood*, **2012**, 120, 3894-3894 | 2.2 | |
| 226 | Autoantigenic Targets of B-Cell Receptors (BCR) Derived From Chronic Lymphocytic Leukemias Bind to and Induce Proliferation of Leukemic Cells.. *Blood*, **2012**, 120, 2884-2884 | 2.2 | |

| | | | |
|---|---|---|---|
| 225 | TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20+ Aggressive B-Cell Lymphoma: Analysis within the Ricover-60 Trial. *Blood*, **2012**, 120, 546-546 | 2.2 | |
| 224 | Telomere Length in Mantle Cell Lymphoma.. *Blood*, **2012**, 120, 2509-2509 | 2.2 | |
| 223 | IL4 and CD40L Prevent Apoptosis of Chronic Lymphocytic Leukemia Cells Via Intracellular pSTAT6 and NFkB Signaling and Not Via Receptor Kinetics. *Blood*, **2012**, 120, 3893-3893 | 2.2 | |
| 222 | Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.. *Blood*, **2012**, 120, 2874-2874 | 2.2 | |
| 221 | The Use of Chemoimmunotherapy Improves the Outcome of Patients with Chronic Lymphocytic Leukaemia (CLL) – a Metaanalysis of Five Trials of the German CLL Study Group (GCLLSG). *Blood*, **2012**, 120, 3936-3936 | 2.2 | |
| 220 | DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. *Blood*, **2011**, 117, 1622-32 | 2.2 | 33 |
| 219 | Immune modulatory agents in hematopoietic malignancies. *Cancer Treatment Reviews*, **2011**, 37 Suppl 1, S2-7 | 14.4 | 1 |
| 218 | Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. *Journal of Clinical Oncology*, **2011**, 29, 3559-66 | 2.2 | 315 |
| 217 | Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. *Blood*, **2011**, 117, 6450-8 | 2.2 | 107 |
| 216 | Genetics of chronic lymphocytic leukemia. *Clinics in Laboratory Medicine*, **2011**, 31, 649-58, ix | 2.1 | 6 |
| 215 | P53 and microRNAs in chronic lymphocytic leukemia. *Journal of Nucleic Acids Investigation*, **2011**, 2, 8 | | 1 |
| 214 | Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. *Blood*, **2011**, 117, 1817-21 | 2.2 | 32 |
| 213 | Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. *Haematologica*, **2011**, 96, 408-16 | 6.6 | 63 |
| 212 | Nurse-like cells show deregulated expression of genes involved in immunocompetence. *British Journal of Haematology*, **2011**, 154, 349-56 | 4.5 | 26 |
| 211 | Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. *European Journal of Haematology*, **2011**, 87, 426-33 | 3.8 | 20 |
| 210 | A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. *Blood*, **2011**, 118, 4159-68 | 2.2 | 85 |
| 209 | Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL. *International Journal of Cancer*, **2011**, 128, 1747-50 | 7.5 | 15 |
| 208 | Importance of genetics in chronic lymphocytic leukemia. *Blood Reviews*, **2011**, 25, 131-7 | 11.1 | 66 |

| | | | |
|---|---|---|---|
| 207 | Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia. *Therapeutic Advances in Hematology*, **2011**, 2, 249-65 | 5.7 | 3 |
| 206 | Treating chronic lymphocytic leukemia with thalidomide and lenalidomide. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 2857-64 | 4 | 13 |
| 205 | MicroRNA-130a Targets ATG2B, AGO4 and DICER1, Inhibits Autophagy and Induces Cell Death in Chronic Lymphocytic Leukemia. *Blood*, **2011**, 118, 1768-1768 | 2.2 | 1 |
| 204 | Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups□Results From the CLL8 Trial of the German CLL Study Group (GCLLSG). *Blood*, **2011**, 118, 1777-1777 | 2.2 | 4 |
| 203 | Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy. *Blood*, **2011**, 118, 1793-1793 | 2.2 | 1 |
| 202 | Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW. *Blood*, **2011**, 118, 2854-2854 | 2.2 | 2 |
| 201 | Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study). *Blood*, **2011**, 118, 2859-2859 | 2.2 | 1 |
| 200 | Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group. *Blood*, **2011**, 118, 2860-2860 | 2.2 | 2 |
| 199 | Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG). *Blood*, **2011**, 118, 977-977 | 2.2 | 2 |
| 198 | Uncovering Thalidomide Mechanism of Action: Neuropilin 1 Represents the Target of Antiangiogenic and Immunomodulatory Effect in Chronic Lymphocytic Leukemia. *Blood*, **2011**, 118, 4608-4608 | 2.2 | |
| 197 | The Toll-Like Receptor-Like Molecule CD180 and Soluble CD14 Transmit Survival Signals in B-Cell Chronic Lymphocytic Leukemia Cells Presumably by Acting As Co-Receptors,. *Blood*, **2011**, 118, 3883-3883 | 2.2 | |
| 196 | Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG). *Blood*, **2011**, 118, 2841-2841 | 2.2 | |
| 195 | Reduced c-FOS Is Associated with Poor Prognosis and Clinical Course in Chronic Lymphocytic Leukemia. *Blood*, **2011**, 118, 2433-2433 | 2.2 | |
| 194 | Role of Microenvironment-Associated Chemokines and Cytokines for Binet Stage A CLL Patients Included in a Prospective Trial (CLL1 trial) of the German CLL Study Group (GCLLSG): sIl2Ralpha Is An Independent Predictor of Progression-Free Survival (PFS),. *Blood*, **2011**, 118, 3869-3869 | 2.2 | |
| 193 | SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). *Blood*, **2011**, 118, 263-263 | 2.2 | |
| 192 | Proposal of A Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on An Overall Survival Analysis of Three German CLL Study Group Phase III Trials. *Blood*, **2011**, 118, 2831-2831 | 2.2 | |
| 191 | Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. *British Journal of Haematology*, **2010**, 148, 948-50 | 4.5 | 50 |
| 190 | SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL). *British Journal of Haematology*, **2010**, 150, 633-6 | 4.5 | 9 |

| | | | |
|---|---|---|---|
| 189 | From pathogenesis to treatment of chronic lymphocytic leukaemia. *Nature Reviews Cancer*, **2010**, 10, 37-50 | 31.3 | 438 |
| 188 | Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2010**, 28, 1749-55 | 2.2 | 483 |
| 187 | Immunoglobulin heavy chain variable gene usage and (super)-antigen drive in chronic lymphocytic leukemia. *Clinical Cancer Research*, **2010**, 16, 373-5 | 12.9 | 3 |
| 186 | Understanding and managing ultra high-risk chronic lymphocytic leukemia. *Hematology American Society of Hematology Education Program*, **2010**, 2010, 481-8 | 3.1 | 96 |
| 185 | More (on) prognostic factors in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2010**, 51, 5-6 | 1.9 | 1 |
| 184 | Chronic lymphocytic leukemia: new concepts for future therapy. *Clinical Lymphoma, Myeloma and Leukemia*, **2010**, 10, 369-78 | 2 | 9 |
| 183 | Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). *Best Practice and Research in Clinical Haematology*, **2010**, 23, 71-84 | 4.2 | 51 |
| 182 | TP53 mutation and survival in chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2010**, 28, 4473-9 | 2.2 | 430 |
| 181 | Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. *Blood*, **2010**, 116, 2438-47 | 2.2 | 240 |
| 180 | Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk. *Haematologica*, **2010**, 95, 1880-8 | 6.6 | 4 |
| 179 | Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. *Haematologica*, **2010**, 95, 102-9 | 6.6 | 24 |
| 178 | Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. *Blood*, **2010**, 115, 4497-506 | 2.2 | 152 |
| 177 | Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. *Blood*, **2010**, 116, 4223-30 | 2.2 | 56 |
| 176 | Highlights der 51. Jahrestagung der American Society of Hematology (ASH) 2009. *Onkopipeline*, **2010**, 3, 52-61 | | |
| 175 | High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay. *International Journal of Cancer*, **2010**, 127, 404-11 | 7.5 | 21 |
| 174 | CD5+ B cells from individuals with systemic lupus erythematosus express granzyme B. *European Journal of Immunology*, **2010**, 40, 2060-9 | 6.1 | 40 |
| 173 | Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma | 2.2 | 21 |
| 172 | Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). *Blood*, **2010**, 116, 1376-1376 | 2.2 | 1 |

| | | | |
|---|---|---|---|
| 171 | Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial. *Blood*, **2010**, 116, 2357-2357 | 2.2 | 1 |
| 170 | Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG. *Blood*, **2010**, 116, 2427-2427 | 2.2 | 9 |
| 169 | High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia. *Blood*, **2010**, 116, 50-50 | 2.2 | 1 |
| 168 | Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL. *Blood*, **2010**, 116, 58-58 | 2.2 | 5 |
| 167 | Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG). *Blood*, **2010**, 116, 918-918 | 2.2 | 2 |
| 166 | Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW. *Blood*, **2010**, 116, 920-920 | 2.2 | 12 |
| 165 | Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. *Blood*, **2010**, 116, 921-921 | 2.2 | 6 |
| 164 | Refractory chronic lymphocytic leukemia - new therapeutic strategies. *Oncotarget*, **2010**, 1, 472-482 | 3.3 | 17 |
| 163 | Refractory chronic lymphocytic leukemia--new therapeutic strategies. *Oncotarget*, **2010**, 1, 472-82 | 3.3 | 11 |
| 162 | IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG). *Blood*, **2010**, 116, 3609-3609 | 2.2 | |
| 161 | Exceptional In Vitro Activity of CD37 Antibodies In CLL. *Blood*, **2010**, 116, 2460-2460 | 2.2 | |
| 160 | Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study. *Blood*, **2010**, 116, 2184-2184 | 2.2 | |
| 159 | Maturation of the miR15a/miR16-1 Family Is Impaired In Chronic Lymphocytic Leukaemia. *Blood*, **2010**, 116, 53-53 | 2.2 | |
| 158 | Chemoimmunotherapy in chronic lymphocytic leukemia. *Clinical Advances in Hematology and Oncology*, **2010**, 8, 867-8 | 0.6 | |
| 157 | BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2009**, 50, 1837-42 | 1.9 | 12 |
| 156 | miR-34a as part of the resistance network in chronic lymphocytic leukemia. *Blood*, **2009**, 113, 3801-8 | 2.2 | 229 |
| 155 | Fatal Ophiostoma piceae infection in a patient with acute lymphoblastic leukaemia. *Journal of Medical Microbiology*, **2009**, 58, 381-385 | 3.2 | 12 |
| 154 | A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. *Cancer Research*, **2009**, 69, 8977-86 | 8.1 | 51 |

| | | | |
|---|---|---|---|
| 153 | Danish CLL2-Study revisited: FISH on a cohort with a 20-yr follow-up confirms the validity of the hierarchical model of genomic aberrations in chronic lymphocytic leukaemia. *European Journal of Haematology*, **2009**, 83, 156-8 | 3.8 | 5 |
| 152 | Chronic lymphocytic leukemia and 13q14: miRs and more. *Leukemia and Lymphoma*, **2009**, 50, 502-5 | 1.9 | 35 |
| 151 | Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. *Blood*, **2009**, 114, 2589-97 | 2.2 | 232 |
| 150 | Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. *Leukemia and Lymphoma*, **2009**, 50, 510-3 | 1.9 | 32 |
| 149 | Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival. *Leukemia and Lymphoma*, **2009**, 50, 1559-61 | 1.9 | 2 |
| 148 | Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. *Journal of Clinical Oncology*, **2009**, 27, 3994-4001 | 2.2 | 230 |
| 147 | TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.. *Blood*, **2009**, 114, 1267-1267 | 2.2 | 6 |
| 146 | Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).. *Blood*, **2009**, 114, 205-205 | 2.2 | 22 |
| 145 | Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.. *Blood*, **2009**, 114, 207-207 | 2.2 | 14 |
| 144 | Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group.. *Blood*, **2009**, 114, 209-209 | 2.2 | 4 |
| 143 | Identification of RHAMM-Derived CD8+ Restricted, Heteroclitical, Cryptic Epitope R9Y as a Promising Target for Immunotherapy of Chronic Lymphocytic Leukemia.. *Blood*, **2009**, 114, 3034-3034 | 2.2 | 1 |
| 142 | Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.. *Blood*, **2009**, 114, 3433-3433 | 2.2 | 4 |
| 141 | First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.. *Blood*, **2009**, 114, 535-535 | 2.2 | 31 |
| 140 | Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.. *Blood*, **2009**, 114, 879-879 | 2.2 | 1 |
| 139 | Comprehensive Protein Expression Analysis of Chronic Lymphocytic Leukemia Uncovers a Correlation of CDK4, P27 and P53 with Hierarchical Risk and Suggests a Dichotomy of Apoptosis and Proliferation.. *Blood*, **2009**, 114, 1255-1255 | 2.2 | |
| 138 | A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia.. *Blood*, **2009**, 114, 731-731 | 2.2 | |
| 137 | Identification and Characterization of Peptide Ligands for Stereotyped Subset and Non-Subset B-Cell Receptors of Patients with M- and U-CLL.. *Blood*, **2009**, 114, 4369-4369 | 2.2 | |
| 136 | In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL.. *Blood*, **2009**, 114, 2379-2379 | 2.2 | 1 |

| | | | |
|---|---|---|---|
| 135 | Detection of NFB Activity in Primary CLL Cells Using a Sensitive Oligo-Based Chemiluminescent ELISA.. *Blood*, **2009**, 114, 4709-4709 | 2.2 | |
| 134 | In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2009**, 114, 4408-4408 | 2.2 | |
| 133 | Neuropilin-1 Novel, Promising Target for Chronic Lymphocytic Leukemia patients.. *Blood*, **2009**, 114, 4392-4392 | 2.2 | 0 |
| 132 | Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. *British Journal of Haematology*, **2008**, 142, 538-50 | 4.5 | 37 |
| 131 | First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine. *Journal of Nuclear Medicine*, **2008**, 49, 1756-62 | 8.9 | 55 |
| 130 | Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications. *Leukemia and Lymphoma*, **2008**, 49, 864-73 | 1.9 | 36 |
| 129 | Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. *Blood*, **2008**, 112, 3322-9 | 2.2 | 322 |
| 128 | Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. *Journal of Clinical Oncology*, **2008**, 26, 5094-100 | 2.2 | 139 |
| 127 | The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. *Haematologica*, **2008**, 93, 1111-3 | 6.6 | 31 |
| 126 | Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. *Cell Cycle*, **2008**, 7, 3810-4 | 4.7 | 66 |
| 125 | Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. *Blood*, **2008**, 111, 2246-52 | 2.2 | 117 |
| 124 | Response: Or both?. *Blood*, **2008**, 111, 5756-5757 | 2.2 | 1 |
| 123 | Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. *Haematologica*, **2008**, 93, 680-7 | 6.6 | 37 |
| 122 | Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. *Haematologica*, **2008**, 93, 1912-6 | 6.6 | 20 |
| 121 | Identification of Genes Associated with Resistance and Response in Vivo to Therapy with Rituximab, Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukemia.. *Blood*, **2008**, 112, 1622-1622 | 2.2 | 2 |
| 120 | Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG.. *Blood*, **2008**, 112, 2089-2089 | 2.2 | 4 |
| 119 | Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.. *Blood*, **2008**, 112, 2104-2104 | 2.2 | 4 |
| 118 | Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial. *Blood*, **2008**, 112, 3139-3139 | 2.2 | 1 |

| | | | |
|---|---|---|---|
| 117 | Induction of Apoptosis in CLL by Peptides Binding the B-Cell Antigen Receptor in Vitro. *Blood*, **2008**, 112, 3151-3151 | 2.2 | 1 |
| 116 | Peptide Vaccination Induces Dynamic Changes in CD4+ and CD8+ T Cell Subsets: Report on the First Peptide Vaccination Trial in Patients with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2008**, 112, 3159-3159 | 2.2 | 2 |
| 115 | Effective Targeting of the PI3-K Pathway in CLL with NVP-BEZ235, a Novel Orally Available Dual PI3K/mTOR Inhibitor. *Blood*, **2008**, 112, 3166-3166 | 2.2 | 1 |
| 114 | Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group. *Blood*, **2008**, 112, 3170-3170 | 2.2 | 2 |
| 113 | Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). *Blood*, **2008**, 112, 325-325 | 2.2 | 78 |
| 112 | Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab – a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial. *Blood*, **2008**, 112, 326-326 | 2.2 | 12 |
| 111 | Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial. *Blood*, **2008**, 112, 328-328 | 2.2 | 21 |
| 110 | Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers. *Blood*, **2008**, 112, 329-329 | 2.2 | 2 |
| 109 | Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG). *Blood*, **2008**, 112, 330-330 | 2.2 | 29 |
| 108 | Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study). *Blood*, **2008**, 112, 565-565 | 2.2 | 4 |
| 107 | Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial. *Blood*, **2008**, 112, 781-781 | 2.2 | 16 |
| 106 | Differential Diagnosis, Staging and Prognostic Factors **2008**, 103-119 | | 2 |
| 105 | Mir-34a as Part of the Chemotherapy Resistance Network in Chronic Lymphocytic Leukemia.. *Blood*, **2008**, 112, 1209-1209 | 2.2 | 1 |
| 104 | The Response to DNA Damage in CLL Cells Is Partly Determined by the Type of TP53 Mutation and Genomic Aberrations. *Blood*, **2008**, 112, 3119-3119 | 2.2 | |
| 103 | Molecular and Immunological Effects of Thalidomide in Chronic Lymphocytic Leukemia.. *Blood*, **2008**, 112, 2092-2092 | 2.2 | |
| 102 | Epimutation of the Tumor Suppressor Mechanism in 13q14.3 Involves Monoallelic Expression, Non-Coding RNA Genes and Deregulation of NFkB Signalling. *Blood*, **2008**, 112, 783-783 | 2.2 | |
| 101 | 17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution. *Blood*, **2008**, 112, 782-782 | 2.2 | 1 |
| 100 | In-Vitro Treatment with the AKT-Inhibitor GSK 690693 Induces Cell Death in Lymphoma Cell Lines and in Primary CLL Cells and Is Followed by Caspase-3 Activation and Cytochrome C Release.. *Blood*, **2008**, 112, 1589-1589 | 2.2 | |

| | | | |
|---|---|---|---|
| 99 | TP53 Abnormalities in Chronic Lymphocytic Leukemia Exhibit a Disease Specific Profile: Meta-Analysis of 270 Mutations.. *Blood*, **2008**, 112, 2077-2077 | 2.2 | |
| 98 | Quantitative Gene Expression Analysis of Surrogate Markers for Genetic Risk Groups and Survival in CLL. *Blood*, **2008**, 112, 4170-4170 | 2.2 | |
| 97 | Advances in the use of alemtuzumab in CLL. *Clinical Advances in Hematology and Oncology*, **2008**, 6, 23-4 | 0.6 | 1 |
| 96 | Update on Genomic Profiling in Chronic Lymphocytic Leukemia. *Clinical Leukemia*, **2007**, 1, 217-222 | | |
| 95 | Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. *Best Practice and Research in Clinical Haematology*, **2007**, 20, 439-53 | 4.2 | 58 |
| 94 | High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia. *International Journal of Cancer*, **2007**, 121, 978-83 | 7.5 | 11 |
| 93 | Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. *International Journal of Cancer*, **2007**, 121, 1984-93 | 7.5 | 50 |
| 92 | Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. *Genes Chromosomes and Cancer*, **2007**, 46, 494-9 | 5 | 61 |
| 91 | Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse. *British Journal of Haematology*, **2007**, 136, 127-30 | 4.5 | 5 |
| 90 | Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. *Journal of Clinical Oncology*, **2007**, 25, 2770-7 | 2.2 | 48 |
| 89 | Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. *Haematologica*, **2007**, 92, 1242-5 | 6.6 | 179 |
| 88 | p53 Inactivation in CLL: Pattern of 110 TP53 Mutations.. *Blood*, **2007**, 110, 2064-2064 | 2.2 | 3 |
| 87 | Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).. *Blood*, **2007**, 110, 3106-3106 | 2.2 | 10 |
| 86 | Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).. *Blood*, **2007**, 110, 3120-3120 | 2.2 | 10 |
| 85 | Thalidomide Alone and in Combination with Fludarabine Exerts Distinct Molecular and Antileukemic Effects in B-Cell Chronic Lymphocytic Leukemia.. *Blood*, **2007**, 110, 3124-3124 | 2.2 | 1 |
| 84 | Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis.. *Blood*, **2007**, 110, 47-47 | 2.2 | 1 |
| 83 | Prospective Evaluation of Prognostic Parameters in Early Stage Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of the German CLL Study Group (GCLLSG).. *Blood*, **2007**, 110, 625-625 | 2.2 | 10 |
| 82 | Prognostic Assessment of Three Single Nucleotide Polymorphisms (BCL2 938C>A, MTHFR 677C>T, GNAS1 T393C) in Chronic Lymphocytic Leukemia.. *Blood*, **2007**, 110, 2080-2080 | 2.2 | |

| | | | |
|---|---|---|---|
| 81 | Gene Expression Signature of B-Cell Chronic Lymphocytic Leukemia with Trisomy 12.. *Blood*, **2007**, 110, 2079-2079 | 2.2 | |
| 80 | In-Vitro Treatment of Lymphoma Cell Lines with BAY 43-9006 (Sorafenib) Is Followed by Typical Features of Apoptosis and Down-Regulation of MCL-1 Pointing to an Efficacy of Sorafenib in the Teatment of Lymphoma.. *Blood*, **2007**, 110, 1392-1392 | 2.2 | |
| 79 | The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.. *Blood*, **2007**, 110, 2051-2051 | 2.2 | |
| 78 | BCRs of Mutated and Unmutated CLL Bind Peptides with Distinct Sequence Features: Evidence from Phage Display Libraries.. *Blood*, **2007**, 110, 1118-1118 | 2.2 | |
| 77 | Uncovering the Epigenetic Pathomechanism in 13q14.. *Blood*, **2007**, 110, 487-487 | 2.2 | |
| 76 | Autoimmune or Chronic Infectious Disease in B-CLL at Diagnosis: Association with Unmutated VH Gene Status and Unfavorable Cytogenetics.. *Blood*, **2007**, 110, 3092-3092 | 2.2 | |
| 75 | Risk stratification in chronic lymphocytic leukemia. *Seminars in Oncology*, **2006**, 33, 186-94 | 5.5 | 62 |
| 74 | Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. *International Journal of Cancer*, **2006**, 118, 1831-5 | 7.5 | 37 |
| 73 | Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 7741-6 | 11.5 | 47 |
| 72 | Molecular imaging of proliferation in malignant lymphoma. *Cancer Research*, **2006**, 66, 11055-61 | 10.1 | 158 |
| 71 | Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2006**, 24, 969-75 | 2.2 | 157 |
| 70 | Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: application in mantle cell lymphoma. *FASEB Journal*, **2006**, 20, 1188-90 | 0.9 | 21 |
| 69 | Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. *Blood*, **2006**, 107, 885-91 | 2.2 | 459 |
| 68 | Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. *Blood*, **2006**, 107, 2889-94 | 2.2 | 149 |
| 67 | Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. *Blood*, **2006**, 107, 2090-3 | 2.2 | 46 |
| 66 | Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemia. *Current Drug Targets*, **2006**, 7, 1313-27 | 3 | 7 |
| 65 | Clonal Evolution in Chronic Lymphocytic Leukemia: Acquisition of High-Risk Genomic Aberrations Associated with Unmutated VH, Resistance to Therapy, and Short Survival.. *Blood*, **2006**, 108, 296-296 | 2.2 | 1 |
| 64 | Occurrence of Chromosomal Translocations as Independent Prognostic Factor in Chronic Lymphocytic Leukemia.. *Blood*, **2006**, 108, 2084-2084 | 2.2 | |

| | | | |
|---|---|---|---|
| 63 | RHAMM/CD168 Is a Novel Leukemia Associated Antigen with Prognostic Value for Patients with B-Cell Chronic Lymphocytic Leukemia.. *Blood*, **2006**, 108, 2773-2773 | 2.2 | |
| 62 | Influence of MDM2 Single Nucleotide Polymorphism SNP309 on Disease Onset and Course in CLL.. *Blood*, **2006**, 108, 4938-4938 | 2.2 | |
| 61 | Array-CGH Based Genomic Profiling in B-Cell Chronic Lymphocytic Leukemia Reveals Specific Correlations of Genomic Imbalances and Prognostic Subgroups and Underlines the Consistency of Chromosomal Aberration Patterns within This Disease.. *Blood*, **2006**, 108, 2083-2083 | 2.2 | |
| 60 | Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation. *Journal of Nuclear Medicine*, **2006**, 47, 278-86 | 8.9 | 16 |
| 59 | 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. *British Journal of Haematology*, **2005**, 130, 604-13 | 4.5 | 84 |
| 58 | Duplication of chromosome arms 9q and 11q: evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma. *Genes Chromosomes and Cancer*, **2005**, 42, 78-81 | 5 | 4 |
| 57 | Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia disrupts two novel genes. *Genes Chromosomes and Cancer*, **2005**, 42, 128-43 | 5 | 29 |
| 56 | Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. *Journal of Clinical Oncology*, **2005**, 23, 3780-92 | 2.2 | 60 |
| 55 | In-Vitro Treatment of Chronic Lymphocytic Leukemia (CLL) Cells with Fludarabine, Etoposide and Alemtuzumab (Campath-1H) Reveals Different Rates and Mechanisms of Cell Death.. *Blood*, **2005**, 106, 2112-2112 | 2.2 | 1 |
| 54 | Fludarabine Versus Fludarabine Plus Epirubicin in the Treatment of Chronic Lymphocytic Leukemia - Final Results of a German Randomized Phase-III Study.. *Blood*, **2005**, 106, 2123-2123 | 2.2 | 3 |
| 53 | Graft Versus Host Disease-Like Syndrome after Autologous Stem Cell Transplantation in CLL Patients Treated with a TBI/Cy/Alemtuzumab (CAMPATH-1H) High-Dose Regimen.. *Blood*, **2005**, 106, 2928-2928 | 2.2 | 1 |
| 52 | 17p Deletion Predicts for Inferior Overall Survival after Fludarabine - Based First Line Therapy in Chronic Lymphocytic Leukemia: First Analysis of Genetics in the CLL4 Trial of the GCLLSG.. *Blood*, **2005**, 106, 715-715 | 2.2 | 36 |
| 51 | The Paternally Expressed Gene 10 (PEG10) on Chromosome 7q21 Is Overexpressed and Imprinted in High-Risk B-CLL.. *Blood*, **2005**, 106, 1221-1221 | 2.2 | |
| 50 | Short Telomeres Are Associated with Genetic Instability and the Occurrence of High Risk Genomic Aberrations in Chronic Lymphocytic Leukemia.. *Blood*, **2005**, 106, 1178-1178 | 2.2 | |
| 49 | Strikingly Homologous Immunoglobulin Gene Rearrangements and Poor Outcome in VH3-21-Utilizing Chronic Lymphocytic Leukemia Independent of Geographical Origin and Mutational Status.. *Blood*, **2005**, 106, 175-175 | 2.2 | |
| 48 | MRD Kinetics Can Predict the Time to Relapse after Autologous Stem Cell Transplantation (SCT) in Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2005**, 106, 714-714 | 2.2 | 1 |
| 47 | ZAP-70 methylation and expression status in chronic lymphocytic leukemia. *Haematologica*, **2005**, 90, 1012 | 6.6 | |
| 46 | Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. *Journal of Clinical Oncology*, **2004**, 22, 3937-49 | 2.2 | 177 |

| | | | |
|---|---|---|---|
| 45 | Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 1039-44 | 11.5 | 206 |
| 44 | Molecular genetics and its clinical relevance. *Hematology/Oncology Clinics of North America*, **2004**, 18, 827-48, viii | 3.1 | 16 |
| 43 | The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. *Blood*, **2004**, 103, 2850-8 | 2.2 | 93 |
| 42 | Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. *Blood*, **2004**, 104, 2600-2 | 2.2 | 139 |
| 41 | Early Autologous Stem Cell Transplantation (SCT) in Genetically Poor-Risk Chronic Lymphocytic Leukemia Is Feasible and Effective: Results from a Prospective Multicenter Study (GCLLSG CLL3 Protocol).. *Blood*, **2004**, 104, 146-146 | 2.2 | 7 |
| 40 | Minimal Residual Disease (MRD) Kinetics after Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) Correlate to IgH VH Mutational Status and Predict Post Transplant Outcome: Real Time ASO-IgH PCR Results of the GCLLSG CLL3 Protocol.. *Blood*, **2004**, 104, 147-147 | 2.2 | 5 |
| 39 | ZAP-70 Expression, VH-Mutation Status, Genomic Aberrations and Prognosis in Chronic Lymphocytic Leukemia.. *Blood*, **2004**, 104, 1920-1920 | 2.2 | 1 |
| 38 | Consolidation with Alemtuzumab in First Remission Induces Pronounced MRD Reduction and Clinical Remissions - Update on a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).. *Blood*, **2004**, 104, 2506-2506 | 2.2 | 3 |
| 37 | Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG).. *Blood*, **2004**, 104, 478-478 | 2.2 | 24 |
| 36 | Protein Expression Patterns of Candidate Genes Involved in Apoptosis and Cell Cycle Control in Genetic Subgroups of Chronic Lymphocytic Leukemia.. *Blood*, **2004**, 104, 2796-2796 | 2.2 | |
| 35 | Prognostic Relevance of Lipoprotein Lipase (LPL) Expression in B-CLL.. *Blood*, **2004**, 104, 177-177 | 2.2 | |
| 34 | Differential Expression Patterns of Apoptotis and Cell Cycle Proteins after Staurosporine Treatment in EHEB (B-CLL) and JURKAT (T-ALL) Cell Lines.. *Blood*, **2004**, 104, 4304-4304 | 2.2 | |
| 33 | Correlation of Quantitative Gene Expression by RQ-PCR with Clinical and Biologic Factors in Mantle Cell Lymphoma.. *Blood*, **2004**, 104, 696-696 | 2.2 | 1 |
| 32 | High ZAP-70 and Differential Expression of B-Cell Receptor Related Genes in Chronic Lymphocytic Leukemia with V3-21 Gene Usage.. *Blood*, **2004**, 104, 773-773 | 2.2 | |
| 31 | Protein Expression Analysis of Chromosome 12 Candidate Genes in Chronic Lymphocytic Leukemia (B-CLL).. *Blood*, **2004**, 104, 4797-4797 | 2.2 | |
| 30 | Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. *Blood*, **2003**, 101, 699-702 | 2.2 | 39 |
| 29 | Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. *Blood*, **2003**, 101, 2049-53 | 2.2 | 102 |
| 28 | VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. *Blood*, **2003**, 102, 3003-9 | 2.2 | 122 |

| | | | |
|---|---|---|---|
| 27 | Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma. *British Journal of Haematology*, **2003**, 122, 193-201 | 4.5 | 30 |
| 26 | Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. *New England Journal of Medicine*, **2002**, 347, 452-3 | 59.2 | 177 |
| 25 | Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. *Blood*, **2002**, 99, 4116-21 | 2.2 | 86 |
| 24 | Pathogenic complexity of gastric B-cell lymphoma. *Blood*, **2002**, 100, 1095-6; author reply 1096-7 | 2.2 | 5 |
| 23 | Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). *American Journal of Pathology*, **2002**, 161, 957-68 | 5.8 | 75 |
| 22 | Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. *Blood*, **2002**, 99, 4554-61 | 2.2 | 117 |
| 21 | V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. *Blood*, **2002**, 100, 1410-1416 | 2.2 | 633 |
| 20 | V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. *Blood*, **2002**, 100, 1410-6 | 2.2 | 155 |
| 19 | CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. *International Journal of Cancer*, **2001**, 91, 474-80 | 7.5 | 93 |
| 18 | Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. *Genes Chromosomes and Cancer*, **2001**, 31, 316-25 | 5 | 73 |
| 17 | B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions. *Human Molecular Genetics*, **2001**, 10, 1275-85 | 5.6 | 70 |
| 16 | t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia **2000**, 27, 285-294 | | 112 |
| 15 | BCMSUN, a candidate gene for B-cell chronic lymphocytic leukemia and mantle-cell lymphoma, has an independently expressed homolog on 1p22-p31, BCMSUN-like. *International Journal of Cancer*, **2000**, 88, 692-7 | 7.5 | 15 |
| 14 | Genomic aberrations and survival in chronic lymphocytic leukemia. *New England Journal of Medicine* , **2000**, 343, 1910-6 | 59.2 | 2573 |
| 13 | Molecular Characterization of 11q Deletions Points to a Pathogenic Role of the ATM Gene in Mantle Cell Lymphoma. *Blood*, **1999**, 94, 3262-3264 | 2.2 | 106 |
| 12 | Somatic ATM Mutations Indicate a Pathogenic Role of ATM in B-Cell Chronic Lymphocytic Leukemia. *Blood*, **1999**, 94, 748-753 | 2.2 | 224 |
| 11 | Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. *Journal of Molecular Medicine*, **1999**, 77, 266-81 | 5.5 | 174 |
| 10 | Exclusive detection of the t(11;18)(q21;q21) in extranodal marginal zone B cell lymphomas (MZBL) of MALT type in contrast to other MZBL and extranodal large B cell lymphomas. *American Journal of Pathology*, **1999**, 155, 1817-21 | 5.8 | 112 |

| | | | |
|---|---|---|---|
| 9 | Expression of costimulatory molecules in low-grade mucosa-associated lymphoid tissue-type lymphomas in vivo. *American Journal of Pathology*, **1999**, 155, 2019-27 | 5.8 | 40 |
| 8 | Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. *Oncogene*, **1998**, 16, 1891-7 | 9.2 | 130 |
| 7 | 11q Deletions Identify a New Subset of B-Cell Chronic Lymphocytic Leukemia Characterized by Extensive Nodal Involvement and Inferior Prognosis. *Blood*, **1997**, 89, 2516-2522 | 2.2 | 328 |
| 6 | Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. *Nature Medicine*, **1997**, 3, 1155-9 | 50.5 | 217 |
| 5 | CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia. *British Journal of Haematology*, **1995**, 91, 865-70 | 4.5 | 19 |
| 4 | Molecular cytogenetic analysis of RB-1 deletions in chronic B-cell leukemias. *Leukemia and Lymphoma*, **1994**, 16, 97-103 | 1.9 | 23 |
| 3 | Reciprocal translocation t(12;13)(p13;q14) in acute nonlymphoblastic leukemia: report and cytogenetic analysis of two cases. *Cancer Genetics and Cytogenetics*, **1994**, 77, 106-10 | | 13 |
| 2 | Chronic Lymphocytic Leukemia: Pathophysiology, Diagnosis and Manifestations, and Prognostic Markers297-307 | | |
| 1 | NOTCH1 drives immune-escape mechanisms in B cell malignancies | | 1 |